A cost-benefit analysis of testing for influenza A in high-risk adults

Annals of Family Medicine

Volumn 2, Issue 1, 2004, Pages 33-40

  Hueston, William J ^a   Benich III, Joseph J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cost benefit analysis; Diagnostic techniques and procedures; Influenza; Virus diseases

Indexed keywords

AMANTADINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR; ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; FLU LIKE SYNDROME; HIGH RISK POPULATION; HUMAN; INFLUENZA VIRUS A; MAJOR CLINICAL STUDY; PREVALENCE; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME; ANALYTICAL EQUIPMENT; DECISION TREE; ECONOMICS; INFLUENZA; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; UNITED STATES;

AGED; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DECISION TREES; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; MIDDLE AGED; MODELS, ECONOMETRIC; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 2142660268     PISSN: 15441709     EISSN: None     Source Type: Journal    
DOI: 10.1370/afm.34     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR Morb Mort Wkly Rep. 2001;50:(RR-41)1-63.
2. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med. 1998;49:85-90.
3. Hak E, Verheij TJ, van Essen GA, Lafeber AB, Grobbee DE, Hoes AW. Prognostic factors for influenza-associated hospitalization and death during an epidemic. Epidemiol Infect. 2001;126:261-268.
4. Treanor JJ, Hayden FH, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA. 2000;283:1016-1024.
5. Jefferson TO, Demicheli V, Deeks JJ, Rivetti D. Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst Rev. 2000;(2):CD001169;10796612.
6. Caserta MT, Hall CB. Antiviral agents for influenza. Pediatr Ann. 2000;29(11):704-711.
7. Monto AS, Moult AB, Sharp SJ. Effect of zanamivir on duration and resolution of influenza symptoms. Clin Ther. 2000;22:1294-1365.
8. Blitz SG, Cram P, Chernew ME, Monto AS, Fendrick AM. Diagnostic testing or empirical neuraminidase inhibitor therapy for patients with influenza-like illness: what a difference a day makes. Am J Manag Care. 2002;8:221-227.
9. Centers for Disease Control and Prevention. Past influenza seasons. Available at: http://www.cdc.gov/nip/flu/flu-seasons.htm. Accessed Feburary 2003.
10. Irwin D, Weatherby LB, Huang WY, Rosenberg DM, Cook SF, Walker AM. Impact of patient characteristics on the risk of influenza/ILI-related complications. Available at: www.biomedcentral.com/1492-6963/1/8. Accessed August 2002.
11. Franham PG, Ackerman SP, Haddix AC, Teutsch SM, Shaffer PA, Dunet DO, eds. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford University Press; 1996; 15-16.
12. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA. 2000;284:1655-1663.
13. Newton DW, Treanor JJ, Menegus MA. Clinical and laboratory diagnosis of influenza virus infections. Am J Man Care. 2000;6:S265-S275.
14. Yamazaki M, Kimura J, Watanabe S, et al. Use of rapid detection assay for influenza viral on nasal aspirate specimens. Kansenshogaku Zasshi. 1999;73:1064-1068.
15. Herrmann B, Larsson C, Zweygberg BW. Simultaneous detection and typing of influenza viruses A and B by a nested reverse transcription-PCR: comparisons to isolation and antigen detection by immunofluorescence and optical immunoassay (FLU OIA). J Clin Microbiol. 2001;39:134-138.
16. Hulson TD, Mold JW, Scheid D, et al. Diagnosing influenza: The value of clinical clues and laboratory tests. J Fam Pract. 2001;50:1051-1056.
17. Boivin G, Hardy I, Kress A. Evaluation of a rapid optical immunoassay for influenza viruses (FLU OIA Test) in comparison with cell culture and reverse transcription-PCR. J Clin Microbiol. 2001;39:730-733.
18. Boon AC, French AM, Fleming DM, Zambon MC. Detection of influenza A subtypes in community-based surveillance. J Med Virology. 2001;65:163-170.
19. Yamazaki M, Mitamura K, Kimura K, et al. Clinical evaluation of an immunochromatography test for rapid diagnosis of influenza. Kansenshogaku Zasshi. 2001;75:1047-1053.
20. Schultze D, Thomas Y, Wunderli W. Evaluation of an optical immunoassay for the rapid detection of influenza A and B viral antigens. Eur J Clin Microbiol Infect Dis. 2001;20:280-283.
21. Shimizu H. The rapid detection kit based on neuraminidase activity of influenza virus. Nippon Rinsho. 2000;58:2234-2237.
22. Nissen D, ed. Mosby's Drug Consults 2002. St Louis, MO: Elvesier Press, Inc; 2002.
23. Physician's Desk Reference. 55th ed. Montvale, NJ: Medical Economics Company, Inc; 2001.
24. Bridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). Morb Mort Week Rep. 2002;51(RR03):1-31.
25. Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C. Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmaco Econ. 2000;17:611-620.